Vertex announces EC approval for ORKAMBI® (lumacaftor/ivacaftor) for children with CF
Vertex announced the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. January 21, 2019